Modern advances in molecular and cellular biology in the treatment of glioblastoma

Gliomas are the most common group of primary brain tumors, accounting for at least 80% of all types of central nervous system neoplasias. High-grade gliomas (anaplastic astrocytoma and oligodendroglioma, anaplastic pleomorphic xanthoastrocytoma, as well as three molecular genetic subtypes of glioblastomas) deserve special attention due to a poor prognosis for patient survival. A search for literature sources in the Russian and foreign databases has demonstrated that there are few studies of new treatments for highgrade gliomas, including glioblastomas. Combining the results of these studies has been an impetus to write this literature review. © I.A. STEPANOV

Authors
Stepanov I.A. , Sorokovikov V.A. , Beloborodov V.A. , Krivoshapkin A.L. , Gaitan A.S. , Shameeva M.A.
Publisher
Общество с ограниченной ответственностью Издательство Медиа Сфера
Number of issue
4
Language
Russian
Pages
66-72
Status
Published
Volume
11
Year
2022
Organizations
  • 1 Irkutsk State Medical University, Ministry of Health of Russia, Irkutsk, Russian Federation
  • 2 Kharlampiev Clinic, Irkutsk, Russian Federation
  • 3 Irkutsk Research Center of Surgery and Traumatology, Irkutsk, Russian Federation
  • 4 People’s Friendship University of Russia, Moscow, Russian Federation
Keywords
blood-brain barrier; glioblastoma; high-grade gliomas; immune therapy; molecular targeted therapy; vaccine therapy
Share

Other records

Rukodainy O.V., Goloshchapov-Aksyonov R.S., Shaburov R.I., Volkov P.S.
Комплексные проблемы сердечно-сосудистых заболеваний. Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний". Vol. 11. 2022. P. 85-97